Arrowhead outlines pivotal 2026 milestones with REDEMPLO launch, $1.33B capital boost, and robust cardiometabolic pipeline (NASDAQ:ARWR)
Earnings Call Insights: Arrowhead Pharmaceuticals (ARWR) Q1 2026 Management View Dr. Christopher Anzalone, Chairman, CEO & President, stated, "We had ...
-1024x683.jpg "Strait Outta Hormuz: Getting the Iran Oil Story Straight")
